Association between motor symptoms and striatal VMAT2 binding in PD: a PET study
Objective: In this study, we investigate the association between motor symptoms and striatal vesicular monoamine transporter type 2 (VMAT2) binding using 18F-FP-DTBZ PET in PD…Utility of VMAT2 inhibitors in management of stereotypy in children: a series of six patients
Objective: We aim to evaluate the effectiveness of VMAT2 inhibitors in the treatment of stereotypy. Background: Stereotypies are continual, rhythmic, patterned movements that can occur in typically-developing children, and are…Comparison of Safety and Tolerability of Deutetrabenazine (DTBZ) During Titration and Maintenance in Patients With Tardive Dyskinesia (TD)
Objective: To compare safety of DTBZ in titration vs maintenance using data from two 12-wk placebo (PBO)-controlled studies (ARM-TD and AIM-TD) and an open-label extension…Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia
Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…The Impact of Antipsychotic Dose Reduction Within a Medicare Population
Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial
Objective: To evaluate the efficacy of deutetrabenazine (DTBZ) in reducing TD in the most severely impacted patients using data from an ongoing open-label extension (OLE)…Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study
Objective: To evaluate long-term efficacy and safety of DTBZ in patients with TD by examining change from baseline in Abnormal Involuntary Movement Scale (AIMS) scores…Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia
Objective: To assess the long-term safety and efficacy of deutetrabenazine in younger (<55 years) and older (≥55 years) patients with tardive dyskinesia (TD). Background: TD…Mechanisms of chronic neuroleptic-induced parkinsonism examined with positron emission tomography
Objective: To investigate the cause of chronic neuroleptic drug-induced parkinsonism (NIP) through examination of the profile of striatal monoaminergic nerve terminal density using positron emission…Patient Perspective of Tardive Dyskinesia: Results from a Social Media Listening Study
Objective: To use social media listening (SML) to understand the impact of symptoms on patients with assumed/self-reported tardive dyskinesia (TD). Background: TD is a persistent…